Prognostic role of METTL1 in glioma

Abstract Background Current treatment options for glioma are limited, and the prognosis of patients with glioma is poor as the available drugs show low therapeutic efficacy. Furthermore, the molecular mechanisms associated with glioma remain poorly understood. METTL1 mainly catalyzes the formation o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lun Li, Yi Yang, Zhenshuang Wang, Chengran Xu, Jinhai Huang, Guangyu Li
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Methyltransferase-like 1 Glioma siRNA CCK8 Biomarker Nomogram Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cytology QH573-671
Acceso en línea:	https://doaj.org/article/1241645914f4426abaf5097b14824ea2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1241645914f4426abaf5097b14824ea2
record_format	dspace
spelling	oai:doaj.org-article:1241645914f4426abaf5097b14824ea22021-11-28T12:37:02ZPrognostic role of METTL1 in glioma10.1186/s12935-021-02346-41475-2867https://doaj.org/article/1241645914f4426abaf5097b14824ea22021-11-01T00:00:00Zhttps://doi.org/10.1186/s12935-021-02346-4https://doaj.org/toc/1475-2867Abstract Background Current treatment options for glioma are limited, and the prognosis of patients with glioma is poor as the available drugs show low therapeutic efficacy. Furthermore, the molecular mechanisms associated with glioma remain poorly understood. METTL1 mainly catalyzes the formation of N(7)-methylguanine at position 46 of the transfer RNA sequence, thereby regulating the translation process. However, the role of METTL1 in glioma has not been studied to date. The purpose of this study was to analyze the expression and prognosis of METTL1 in glioma, and to explore the potential analysis mechanism. Methods Data from five publicly available databases were used to analyze METTL1 expression across different tumor types and its differential expression between carcinoma and adjacent normal tissues. The expression of METTL1 in glioma was further validated using real-time polymerase chain reaction and immunohistochemistry. Meanwhile, siRNA was used to knockdown METTL1 in U87 glioma cells, and the resultant effect on glioma proliferation was verified using the Cell Counting Kit 8 (CCK8) assay. Furthermore, a nomogram was constructed to predict the association between METTL1 expression and the survival rate of patients with glioma. Results METTL1 expression increased with increasing glioma grades and was significantly higher in glioma than in adjacent noncancerous tissues. In addition, high expression of METTL1 promoted cell proliferation. Moreover, METTL1 expression was associated with common clinical risk factors and was significantly associated with the prognosis and survival of patients with glioma. Univariate and multivariate Cox regression analyses revealed that METTL1 expression may be used as an independent prognostic risk factor for glioma. Furthermore, results of functional enrichment and pathway analyses indicate that the mechanism of METTL1 in glioma is potentially related to the MAPK signaling pathway. Conclusions High METTL1 expression is significantly associated with poor prognosis of patients with glioma and may represent a valuable independent risk factor. In addition, high expression of METTL1 promotes glioma proliferation and may regulate mitogen-activated protein kinase (MAPK) signaling pathway. Thus, METTL1 may be a potential biomarker for glioma. Further investigations are warranted to explore its clinical use.Lun LiYi YangZhenshuang WangChengran XuJinhai HuangGuangyu LiBMCarticleMethyltransferase-like 1GliomasiRNACCK8BiomarkerNomogramNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282CytologyQH573-671ENCancer Cell International, Vol 21, Iss 1, Pp 1-20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Methyltransferase-like 1 Glioma siRNA CCK8 Biomarker Nomogram Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cytology QH573-671
spellingShingle	Methyltransferase-like 1 Glioma siRNA CCK8 Biomarker Nomogram Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cytology QH573-671 Lun Li Yi Yang Zhenshuang Wang Chengran Xu Jinhai Huang Guangyu Li Prognostic role of METTL1 in glioma
description	Abstract Background Current treatment options for glioma are limited, and the prognosis of patients with glioma is poor as the available drugs show low therapeutic efficacy. Furthermore, the molecular mechanisms associated with glioma remain poorly understood. METTL1 mainly catalyzes the formation of N(7)-methylguanine at position 46 of the transfer RNA sequence, thereby regulating the translation process. However, the role of METTL1 in glioma has not been studied to date. The purpose of this study was to analyze the expression and prognosis of METTL1 in glioma, and to explore the potential analysis mechanism. Methods Data from five publicly available databases were used to analyze METTL1 expression across different tumor types and its differential expression between carcinoma and adjacent normal tissues. The expression of METTL1 in glioma was further validated using real-time polymerase chain reaction and immunohistochemistry. Meanwhile, siRNA was used to knockdown METTL1 in U87 glioma cells, and the resultant effect on glioma proliferation was verified using the Cell Counting Kit 8 (CCK8) assay. Furthermore, a nomogram was constructed to predict the association between METTL1 expression and the survival rate of patients with glioma. Results METTL1 expression increased with increasing glioma grades and was significantly higher in glioma than in adjacent noncancerous tissues. In addition, high expression of METTL1 promoted cell proliferation. Moreover, METTL1 expression was associated with common clinical risk factors and was significantly associated with the prognosis and survival of patients with glioma. Univariate and multivariate Cox regression analyses revealed that METTL1 expression may be used as an independent prognostic risk factor for glioma. Furthermore, results of functional enrichment and pathway analyses indicate that the mechanism of METTL1 in glioma is potentially related to the MAPK signaling pathway. Conclusions High METTL1 expression is significantly associated with poor prognosis of patients with glioma and may represent a valuable independent risk factor. In addition, high expression of METTL1 promotes glioma proliferation and may regulate mitogen-activated protein kinase (MAPK) signaling pathway. Thus, METTL1 may be a potential biomarker for glioma. Further investigations are warranted to explore its clinical use.
format	article
author	Lun Li Yi Yang Zhenshuang Wang Chengran Xu Jinhai Huang Guangyu Li
author_facet	Lun Li Yi Yang Zhenshuang Wang Chengran Xu Jinhai Huang Guangyu Li
author_sort	Lun Li
title	Prognostic role of METTL1 in glioma
title_short	Prognostic role of METTL1 in glioma
title_full	Prognostic role of METTL1 in glioma
title_fullStr	Prognostic role of METTL1 in glioma
title_full_unstemmed	Prognostic role of METTL1 in glioma
title_sort	prognostic role of mettl1 in glioma
publisher	BMC
publishDate	2021
url	https://doaj.org/article/1241645914f4426abaf5097b14824ea2
work_keys_str_mv	AT lunli prognosticroleofmettl1inglioma AT yiyang prognosticroleofmettl1inglioma AT zhenshuangwang prognosticroleofmettl1inglioma AT chengranxu prognosticroleofmettl1inglioma AT jinhaihuang prognosticroleofmettl1inglioma AT guangyuli prognosticroleofmettl1inglioma
_version_	1718407875366223872

Prognostic role of METTL1 in glioma

Ejemplares similares